Browsing Category
Trending
Kinetix Group Care Delivery Services associates with PTS Diagnostics
The Kinetix Group Care Delivery Services has launched a Real World Evidence model,focusing on diabetes and cardiovascular conditions. As a part of this initiative, we have partnered…
Read More...
Read More...
MAIA Pharmaceuticals sought approval by FDA for NDA for Sincalide for injection
MAIA Pharmaceuticals, NJ based specialty pharmaceutical company asserted tentative approval of Sincalide for Injection NDA by the U.S. Food and Drug Administration.
As far as 2013 is…
Read More...
Read More...
BioAtla enlists first patient in Phase 1/2 BA3011-001 Clinical Trial for CAB-AXL-ADC Therapeutic
BioAtla which is a global biotechnology company aiming to develop Conditionally Active Biologic protein Therapeutics announced the treatment of first patient in its clinical trial…
Read More...
Read More...
Sangamo seeks MHRA authorization for CTA for Phase 1/2 Clinical Trial assessing SB-FIX
Sangamo Therapeutics declared that the Medicines and Healthcare Products Regulatory Agency of the United Kingdom has extended Clinical Trial Authorization for enlisting subjects into…
Read More...
Read More...
MabVax Therapeutics affirms positive results from Phase1 Clinical trial reviewing MVT-1075
MabVax Therapeutics , a clinical-stage biotechnology company that aims to develop antibody-based products to address unattainable medical needs to treat cancer declared positive results…
Read More...
Read More...
CMIC Holdings and Median Technologies venture into agreement ensuring Clinical Trial Services
Median Technologies, the industry-leading Imaging Phenomics Company and CMIC HOLDINGS Co., Ltd. (CMIC), a leading Contract Research Organization (CRO) with services for development,…
Read More...
Read More...
Dr. Sarah Schlesinger appointed to The Medicines Company’s Board of Directors
The Medicines Company declared that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately.
Dr. Schlesinger…
Read More...
Read More...
Invicro appoints Edward Hogan as Senior VP of Clinical Operations
Invicro, a Konica Minolta company asserted that Mr. Edward Hogan, M.S has been appointed as Senior Vice President of Clinical Operations. Mr. Hogan brings extensive medical imaging and…
Read More...
Read More...
ENYO Pharma assures Phase Ib Trial in Chronic HBV afflicted Patients
ENYO Pharma SA declared that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. ENYO Pharma also confirms that its…
Read More...
Read More...
ALung enrolls pivotal Trial of Hemolung RAS for US Market
ALung Technologies asserted that it has initiated enrolling patient in its VENT-AVOID Trial of the Hemolung RAS. The Minneapolis Heart Institute Foundation recently enrolled the first…
Read More...
Read More...
Acclarent received FDA Clearance for AERA Eustachian Tube Balloon Dilation System
Johnson and Johnson Medical Companies asserted that Acclarent,Inc which is a leader in developing minimally-invasive Ear, Nose and Throat technologies has sought clearance from the U.S…
Read More...
Read More...
FDA approves ground breaking treatment for Obstructive Sleep Disorders
Houston-based company specializing in dental sleep medicine and sleep apnea treatment, The Center for Craniofacial & Dental Sleep Medicine (CFDSM) assured that it has sought FDA…
Read More...
Read More...
Sierra Oncology signs Supply Agreement for Prostate Cancer Study
Sierra Oncology which is a clinical stage drug development company aiming to further the DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today…
Read More...
Read More...
Aldeyra Therapeutics forays into agreement with Johnson and Johnson
Aldeyra Therapeutics enters into a collaborative research agreement with Janssen Research and Development, LLC which is ideally one of the Janssen Pharmaceutical Companies of Johnson…
Read More...
Read More...
Amgen sought Positive CHMP opinion for Neulasta Onpro kit
Amgen asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending a label variation for Neulasta…
Read More...
Read More...
Abbott and Surmodics venture into agreement for SurVeil drug-coated balloon
Abbott and Surmodics proclaimed having forayed into an agreement wherein Abbott will possess exclusive commercialization rights for Surmodic's Surveil drug-coated balloon to treat the…
Read More...
Read More...
Lilly sought FDA approval for Verzenio for Advanced Breast Cancer
Eli Lilly and Company proclaimed that the USFood and Drug Administration has sanctioned Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based…
Read More...
Read More...
Vertex appoints Reshma Kewalramani, MD., as Chief Medical Officer
Vertex Pharmaceuticals asserted that Reshma Kewalramani, MD., has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs,…
Read More...
Read More...
Shionogi sought FDA NDA and EMA MAA for lusutrombopag (S-888711)
Shionogi asserted that the NDA for lusutrombopag (S-888711), an investigational, once-daily, orally administered , small molecule thrombopoietin (TPO) receptor agonist, has been…
Read More...
Read More...
Evidence-Based Oncology imparts Biomarkers and CAR T-cell Coverage
Therapy combinations, Biomarkers and the challenge of prayer coverage for CAR T-cell therapy are the topics selected for this year's special tissue on immuno-oncology in Evidence-Based…
Read More...
Read More...